Tempus AI Inc. (NASDAQ: TEM) reported results from the ALERT trial showing that automated electronic health record notifications improved treatment outcomes for patients with significant valvular heart disease. The study was conducted in collaboration with Medtronic and presented at the American College of Cardiology's 75th Annual Scientific Session.

The multicenter, cluster-randomized trial included 765 clinicians and 2,016 echocardiograms across five U.S. health systems and 35 hospitals. The study met its primary endpoint with a win ratio of 1.27, indicating patients receiving automated alerts were 27% more likely to be evaluated by a multidisciplinary heart team or receive a valve intervention compared to usual care.

The AI-driven system delivered a 40% relative increase in valve procedures within 90 days, with 13.4% of alert group patients receiving interventions versus 9.6% in the usual care group. Multidisciplinary heart team evaluations increased 27%, reaching 22.7% in the alert group compared to 17.9% in usual care.

The automated system uses Tempus Next platform with natural language processing to extract findings from echocardiogram reports and deliver real-time notifications to healthcare providers. The notifications were designed to be device-agnostic, not requiring specific Medtronic devices for recommended treatments.

"The ALERT trial shows that data-driven clinical decision support positively impacts patients suffering from valvular heart disease," said Brandon Fornwalt, senior vice president of cardiology at Tempus.

Valvular heart disease affects patient outcomes significantly, with untreated symptomatic severe aortic stenosis showing mortality rates approaching 50% within two years, according to the company's press release statement.